JP2017502984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502984A5 JP2017502984A5 JP2016546483A JP2016546483A JP2017502984A5 JP 2017502984 A5 JP2017502984 A5 JP 2017502984A5 JP 2016546483 A JP2016546483 A JP 2016546483A JP 2016546483 A JP2016546483 A JP 2016546483A JP 2017502984 A5 JP2017502984 A5 JP 2017502984A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- group
- functional group
- cyclodextrin
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927259P | 2014-01-14 | 2014-01-14 | |
| US61/927,259 | 2014-01-14 | ||
| US201461992572P | 2014-05-13 | 2014-05-13 | |
| US61/992,572 | 2014-05-13 | ||
| PCT/US2015/011344 WO2015108933A1 (en) | 2014-01-14 | 2015-01-14 | Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502984A JP2017502984A (ja) | 2017-01-26 |
| JP2017502984A5 true JP2017502984A5 (enExample) | 2018-02-22 |
| JP6552509B2 JP6552509B2 (ja) | 2019-07-31 |
Family
ID=53543385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546483A Active JP6552509B2 (ja) | 2014-01-14 | 2015-01-14 | 選択的ａｔｐ阻害剤をカプセル化するシクロデキストリン組成物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9737487B2 (enExample) |
| EP (1) | EP3094317B1 (enExample) |
| JP (1) | JP6552509B2 (enExample) |
| CN (2) | CN115054698B (enExample) |
| AU (1) | AU2015206629B2 (enExample) |
| CA (1) | CA2936940C (enExample) |
| WO (1) | WO2015108933A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2331092T3 (da) | 2008-08-21 | 2014-05-19 | Univ Johns Hopkins | Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer |
| WO2017079563A1 (en) | 2015-11-06 | 2017-05-11 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
| WO2018152332A1 (en) * | 2017-02-15 | 2018-08-23 | Henry Ford Health System | Applications of pair-production for improved radiotherapy |
| JP7670278B2 (ja) | 2019-10-04 | 2025-04-30 | 国立大学法人 熊本大学 | 薬物キャリア剤及びその製造方法 |
| EP4041116A4 (en) * | 2019-10-11 | 2023-12-13 | Dentosity, LLC | IMPROVED LIGHT-BASED DENTAL TREATMENT DEVICE |
| WO2022055748A1 (en) * | 2020-09-08 | 2022-03-17 | The Johns Hopkins University | Encapsulated agents that bind to mct-1 |
| US20230190660A1 (en) * | 2021-12-03 | 2023-06-22 | Path | Encapsulated pharmaceutical compositions, related methods of making, and related methods of treatment |
| WO2024243178A1 (en) * | 2023-05-22 | 2024-11-28 | The Johns Hopkins University | Cyclodextrin compositions encapsulating alkylating agents and uses thereof |
| WO2024246220A1 (en) * | 2023-05-31 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating lung cancer |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4337760A (en) | 1978-10-13 | 1982-07-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
| DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
| US5800820A (en) | 1989-01-10 | 1998-09-01 | Repligen Corporation | Methods and compositions for treatment of angiogenic diseases |
| US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IT1263831B (it) * | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| WO1997004104A2 (en) | 1995-07-14 | 1997-02-06 | The Johns Hopkins University | Tumor type ii hexokinase transcription regulatory regions |
| US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| US6284786B1 (en) | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
| US20020006915A1 (en) | 2000-02-15 | 2002-01-17 | Mack Strong Vivian E. | Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| AU2001245766A1 (en) | 2000-03-14 | 2001-09-24 | The Johns Hopkins University School Of Medicine | Arrest of proliferation of highly glycolytic tumors |
| US6670330B1 (en) | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| AU2002233916A1 (en) | 2000-08-03 | 2002-04-29 | Albert Einstein College Of Medicine | Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection |
| US7381713B2 (en) | 2000-12-04 | 2008-06-03 | Sioan-Kettering Institute For Cancer Research | Treatment of cancer by reduction of intracellular energy and pyrimidines |
| US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| US7071163B2 (en) | 2002-08-05 | 2006-07-04 | Mirus Bio Corporation | Compounds for targeting hepatocytes in vivo |
| CA2513399A1 (en) | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| WO2004064735A2 (en) | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Treatment of benign prostatic hyperplasia |
| TW200612917A (en) | 2004-07-08 | 2006-05-01 | Threshold Pharmaceuticals Inc | Prevention of cancer |
| CA2575367A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| US7754693B2 (en) | 2006-02-16 | 2010-07-13 | Young Hee Ko | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| CN101951930A (zh) | 2008-02-19 | 2011-01-19 | 阿奈斯特药品株式会社 | 对身体功能的恢复有用的口服或经肠组合物 |
| AU2009259853A1 (en) * | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| DK2331092T3 (da) * | 2008-08-21 | 2014-05-19 | Univ Johns Hopkins | Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer |
| WO2012047339A2 (en) * | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| WO2014004651A1 (en) * | 2012-06-26 | 2014-01-03 | The Johns Hopkins University | Multifunctional tunable biomaterials for tissue engineering |
-
2015
- 2015-01-14 JP JP2016546483A patent/JP6552509B2/ja active Active
- 2015-01-14 WO PCT/US2015/011344 patent/WO2015108933A1/en not_active Ceased
- 2015-01-14 AU AU2015206629A patent/AU2015206629B2/en active Active
- 2015-01-14 CN CN202210378454.7A patent/CN115054698B/zh active Active
- 2015-01-14 CA CA2936940A patent/CA2936940C/en active Active
- 2015-01-14 CN CN201580013842.3A patent/CN106102725A/zh active Pending
- 2015-01-14 EP EP15737304.4A patent/EP3094317B1/en active Active
- 2015-03-10 US US14/643,603 patent/US9737487B2/en active Active
-
2017
- 2017-07-14 US US15/650,317 patent/US20180008541A1/en not_active Abandoned
-
2019
- 2019-02-26 US US16/285,999 patent/US20190328666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502984A5 (enExample) | ||
| Vogus et al. | A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer | |
| JP2019509339A5 (enExample) | ||
| JP2017502985A5 (enExample) | ||
| JP2015536996A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2012509349A5 (enExample) | ||
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| JP2016536286A5 (enExample) | ||
| JP2016516068A5 (enExample) | ||
| JP2019521180A5 (enExample) | ||
| JP2016505044A5 (enExample) | ||
| JP2017521486A5 (enExample) | ||
| JP2010528045A5 (enExample) | ||
| CN109970987A (zh) | Mof材料、纳米载药材料、药物组合物及其应用 | |
| JP2016531895A5 (enExample) | ||
| JP2012516358A5 (enExample) | ||
| Groer et al. | Intratumoral cancer chemotherapy with a carrier-based immunogenic cell-death eliciting platinum (IV) Agent | |
| JP2014523413A5 (enExample) | ||
| JP2018527360A5 (enExample) | ||
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| JP2017506640A5 (enExample) | ||
| JP2019513828A5 (enExample) | ||
| JP2015534990A5 (enExample) |